targeted cancer therapy Archives
Targeted therapy for neuroendocrine tumors
Feb. 16, 2023—Cancer therapies that target VEGF receptor appear safe and effective for patients with pancreatic and non-pancreatic neuroendocrine tumors, meta-analysis of phase 2/3 clinical trials demonstrates.
Targeted cancer drug during pregnancy
Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.
Molecular testing across tumor types
Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.
Melanoma treatment response
Feb. 24, 2022—Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.
Treating metastatic prostate cancer
Jun. 22, 2021—An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer.
Study reframes approach to targeted therapy resistance
Apr. 11, 2019—When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.
PET imaging to predict tumor response
Jun. 14, 2017—A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.
Drug combos for glioblastoma
May. 3, 2016—Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.
IOM study calls for better evidence for biomarker tests
Mar. 10, 2016—Biomarker tests that help determine which patients may benefit from molecularly targeted therapies need better evidence and oversight to improve their effectiveness and availability, according to a study by the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine.
Overcoming lung cancer drug resistance
Feb. 10, 2016—Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients.
Limiting breast cancer metastasis
Aug. 28, 2014—Vanderbilt researchers have identified a new target for blocking breast cancer metastasis.
Drug discovery clues in network map
Aug. 5, 2014—Vanderbilt investigators have constructed a network map that could guide the development of new targeted cancer therapies.
